RESEARCH - Peptide P140 a promising treatment for SLE

[Guest guest]

NEW YORK (Reuters Health) Dec 09 - Immunotherapy with the novel

investigational agent spliceosomal peptide P140 (IPP-201101; Lupuzor)

safely improves the clinical and biological status of patients with

systemic lupus erythematosus (SLE), according to results of an early

phase II clinical trial.

P140 is an analog of a nuclear protein epitope recognized by lupus

CD4+ cells, the researchers explain in the December issue of Arthritis

& Rheumatism.

In a murine model of lupus, peptide P140 appeared to " initiate a

mechanism of so-called tolerance spreading and reorient, at least

transiently, the deleterious autoimmune response, " write Dr. Sylviane

Muller at the Centre National de la Recherche Scientifique in

Strasbourg, France, and colleagues.

********************************

Read the entire article here:

http://www.medscape.com/viewarticle/584978

Not an MD